Amgen Management

Management criteria checks 3/4

Amgen's CEO is Bob Bradway, appointed in May 2010, has a tenure of 13.58 years. total yearly compensation is $21.40M, comprised of 8% salary and 92% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth CHF142.11M. The average tenure of the management team and the board of directors is 5.6 years and 8.2 years respectively.

Key information

Bob Bradway

Chief executive officer

US$21.4m

Total compensation

CEO salary percentage	8.0%
CEO tenure	13.6yrs
CEO ownership	0.1%
Management average tenure	5.6yrs
Board average tenure	8.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Bradway's remuneration changed compared to Amgen's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b
Sep 30 2017	n/a	n/a	US$8b
Jun 30 2017	n/a	n/a	US$8b
Mar 31 2017	n/a	n/a	US$8b
Dec 31 2016	US$17m	US$2m	US$8b

Compensation vs Market: Bob's total compensation ($USD21.40M) is above average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.

CEO

Bob Bradway (60 yo)

13.6yrs

Tenure

US$21,399,733

Compensation

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Bradway	Chairman	13.6yrs	US$21.40m	0.11% $ 142.1m
Peter Griffith	Executive VP & CFO	3.9yrs	US$7.07m	0.0032% $ 4.1m
Esteban Santos	Executive Vice President of Operations	7.4yrs	US$6.72m	0.0099% $ 12.5m
David Reese	Executive Vice President of Research & Development	5.9yrs	US$7.33m	0.0078% $ 9.9m
Murdo Gordon	Executive VP of Global Commercial Operations	5.3yrs	US$7.72m	0.0059% $ 7.4m
Matthew Busch	Chief Accounting Officer & VP of Finance	less than a year	no data	0.00047% $ 595.8k
Mike Zahigian	Senior VP & Chief Information Officer	4.9yrs	no data	no data
Arvind Sood	Vice President of Investor Relations	19.3yrs	no data	no data
Jonathan Graham	Executive VP	8.4yrs	US$7.24m	0.0032% $ 4.0m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	3.9yrs	no data	0.0015% $ 1.9m
Derek Miller	Senior Vice President of Human Resources	1.9yrs	no data	0.00095% $ 1.2m
Gilles Marrache	Senior VP & Regional GM	7.9yrs	no data	no data

5.6yrs

Average Tenure

55.5yo

Average Age

Experienced Management: 000907582's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Bradway	Chairman	12.2yrs	US$21.40m	0.11% $ 142.1m
Ronald Sugar	Independent Director	13.4yrs	US$380.82k	no data
Robert Eckert	Lead Independent Director	11yrs	US$419.77k	0.0013% $ 1.7m
Amy Miles	Independent Director	3.4yrs	US$359.81k	0.000080% $ 101.4k
Charles Holley	Independent Director	6.8yrs	US$369.77k	0.00024% $ 304.2k
Greg Garland	Independent Director	10.2yrs	US$379.77k	0.0020% $ 2.5m
Ellen Kullman	Independent Director	7.2yrs	US$359.91k	0.000080% $ 101.4k
Brian Druker	Independent Director	5.6yrs	US$359.77k	no data
Tyler Jacks	Independent Director	11.6yrs	US$359.77k	0.00051% $ 646.5k
Wanda Austin	Independent Director	6yrs	US$359.77k	0.00091% $ 1.2m
R. Williams	Independent Director	9.2yrs	US$359.94k	0.00099% $ 1.3m
S. Ishrak	Independent Director	2.4yrs	US$359.89k	0.00017% $ 215.5k

8.2yrs

Average Tenure

67yo

Average Age

Experienced Board: 000907582's board of directors are considered experienced (8.2 years average tenure).

Amgen Management

Management criteria checks 3/4

Key information

Recent management updates

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Insider recently sold CHF2.2m worth of stock

Amgen Inc. Announces Management Changes

Lead Independent Director recently sold CHF1.6m worth of stock

Recent updates

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold CHF2.2m worth of stock

Upcoming dividend of US$2.13 per share at 3.3% yield

Amgen Inc. Announces Management Changes

Second quarter 2023 earnings released: EPS: US$2.58 (vs US$2.46 in 2Q 2022)

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Amgen Announces ECOG-ACRIN Cancer Research Group Results

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Amgen Presents New AMG 133 Phase 1 Clinical Data At Wcirdc 2022

Amgen Inc. Presents New Phase 2 Data That Show Olpasiran Delivers Significant Reduction in Lipoprotein(A) Levels

Amgen Inc. Provides Earnings Guidance for the Year 2022

Amgen Inc. to Report Q3, 2022 Results on Nov 03, 2022

Amgen Declares Dividend for the Third Quarter of 2022, Payable on December 8, 2022

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Amgen Announces Lumakras (Sotorasib) Combined with Vectibix (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Announces Detailed Results from the Global Phase 3 CodeBreak 200 Trial

Amgen Announces Positive New Data At EADV 2022 for Otezla® (Apremilast)

Amgen Announces Topline Data from LUMAKRAS® (sotorasib) Phase 3 Trial in Non-Small Cell Lung Cancer

Amgen Presents New Compelling Data from the Phase 3 FOURIER Open Label Extension (OLE) Studies of Repatha®

Lead Independent Director recently sold CHF1.6m worth of stock

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age